+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Fertility Testing Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • PDF Icon


  • 120 Pages
  • February 2024
  • Region: Global
  • Mordor Intelligence
  • ID: 4622370
The Global Fertility Testing Devices Market size is estimated at USD 669.48 million in 2024, and is expected to reach USD 956.65 million by 2029, growing at a CAGR of 7.40% during the forecast period (2024-2029).

Key Highlights

  • The market was negatively impacted by COVID-19 in 2020. Presently the market has now reached pre-pandemic levels. Over the medium term, increasing awareness and favorable government policies and non-government initiatives for curbing air pollution are expected to drive the market's growth.
  • On the other hand, the high costs of air quality monitoring systems are expected to hamper the growth of the Asia Pacific air quality monitoring market during the forecast period. Nevertheless, increasing technological advancements in air quality monitoring systems will likely create lucrative growth opportunities for the Asia Pacific air quality monitoring market in the forecast period.
  • China dominates the market and is likely to witness the highest CAGR during the forecast period. Increasing awareness of air quality among the public and governments across the country, coupled with supportive government policies.

Fertility Testing Devices Market Trends

Ovulation Prediction Kits are expected to Witness Healthy Growth over the Forecast Period

The pandemic has had mixed effects on the ovulation kit segment. On one hand, due to the luxury of time offered by the lockdowns, many couples planned for a conception during the pandemic. On the other hand, many organizations estimate that the economic crisis during COVID-19, as well as the resulting unemployment, a surge in domestic violence, and restricted access to healthcare during the antenatal period will affect birth rates, resulting in fewer million babies.

Organizations that deal with reproductive health are recommending, out of caution and concern for the lack of data (regarding the relationship between pregnancy and COVID-19), that couples planning pregnancies should hold off for the time being. The European Society of Human Reproduction and Embryology states that all fertility patients considering or planning treatment, even if they do not meet the diagnostic criteria for COVID-19 infection, should avoid becoming pregnant at this time.

OPKs or ovulation prediction kits are used to detect the exact day of ovulation for a woman who is planning for a conception. There are many kinds of ovulation prediction kits in the market. Most of the kits work by measuring the luteinizing hormone (LH) in the urine. LH levels rise 24-36 hours before ovulation. The high level of LH indicates that the release of the egg (ovulation) usually occurs 12-24 hours after the test turns positive.

According to the Centers for Disease Control, one in eight couples has trouble conceiving or sustaining a pregnancy, due to age, health issues, or other factors. This indicates that there is a need in the market for cost-efficient and accurate ovulation monitors. As OPK provides cost-effective fertility testing, its demand is increasing.

United States holds the Significant Revenue Share in the North America Region

In June 2021, the Brookings Institution estimated that in the United States, public health crisis and associated recession will result in 300,000 to 500,000 fewer births in 2021. According to the Guttmacher Institute survey, 2020, 34% of American women have either delayed their plans to have a child or reduced the number of children they expect to have because of the pandemic.

In 2018, the United States experienced a record low fertility rate. The fertility rate in the United States in 2018 was 1.776 births per woman, a 1.11% decline from 2017 (1.796). The number of births in the country dropped by 2% between 2016 and 2017, to 60.2 births per 1,000 women aged 15-44 years, continuing a general downward trend that started with the Great Recession of 2008. This marks the lowest that the fertility rate of the country has been in 30 years. According to the National Center for Health Statistics (2017), birthrates declined to record lows among all groups under the age of 30. Among women aged 20-24 years, the decline was 4%, whereas for women aged 25-29 years, the rate fell to 2%.

According to CDC, in 2019, about 6% of married women aged 15-44 years in the United States were unable to conceive after one year of trying. Moreover, about 12% of women aged 15-44 years in the United States have difficulty conceiving or sustaining a pregnancy.

Hence, the decreasing fertility rates and rising awareness about fertility testing are driving the fertility testing device market in the country.

Fertility Testing Devices Industry Overview

The market studied is moderately competitive and there are several local as well as international companies present in the market. Several companies are focusing on the new product launches to sustain their competitiveness and it has been observed that few new companies are entering the market studied, which is increasing the competition.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Decreasing Fertility Rates
4.2.2 Rising Awareness about Fertility Testing Devices
4.2.3 Launch of Advanced, Easy-to-use Fertility Monitors With High Accuracy
4.3 Market Restraints
4.3.1 High Price of Ovulation Monitors
4.3.2 Lack of Predictive Accuracy to Confirm Ovulation
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Product
5.1.1 Ovulation Prediction Kits
5.1.2 Fertility Monitors Urine-based Ovulation Kits Saliva-based Ovulation Kits Other Fertility Monitors
5.1.3 Male Fertility Testing Products
5.2 By Mode of Purchase
5.2.1 OTC-based
5.2.2 Prescription-based
5.3 By Application
5.3.1 Female Fertility Testing
5.3.2 Male Fertility Testing
5.4 By End User
5.4.1 Home Care Settings
5.4.2 Hospitals/Fertility Clinics
5.5 Geography
5.5.1 North America United States Canada Mexico
5.5.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.5.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.5.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.5.5 South America Brazil Argentina Rest of South America
6.1.1 Church & Dwight Co. Inc.
6.1.2 Fairhaven Health LLC
6.1.3 Fertility Focus Limited
6.1.4 Geratherm Medical AG
6.1.5 HiLin Life Products Inc.
6.1.6 Prestige Brands Holdings Inc.
6.1.7 Quidel Corporation
6.1.8 Swiss Precision Diagnostics GmbH
6.1.9 Advacare Pharma
6.1.10 Babystart
6.1.11 Biozhena
6.1.12 Alere Inc.
6.1.13 Procter & Gamble Company
6.1.14 Uebe Medical GmbH
6.1.15 Samplytics Technologies Private Limited.
6.1.16 Tempdrop LLC
6.1.17 Valley Electronics
6.1.19 Ava Science Inc.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Church & Dwight Co. Inc.
  • Fairhaven Health LLC
  • Fertility Focus Limited
  • Geratherm Medical AG
  • HiLin Life Products Inc.
  • Prestige Brands Holdings Inc.
  • Quidel Corporation
  • Swiss Precision Diagnostics GmbH
  • Advacare Pharma
  • Babystart
  • Biozhena
  • Alere Inc.
  • Procter & Gamble Company
  • Uebe Medical GmbH
  • Samplytics Technologies Private Limited.
  • Tempdrop LLC
  • Valley Electronics
  • Ava Science Inc.